From Bio Co., Ltd.
KKRX:3772202,260.00
KRW
-115.00
(-4.84%)
ISIN
KR7377220009
Return %
Stock
S&P 500
1Y
-70.01
14.20
3Y
-85.70
81.12
5Y
-93.70
68.34
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- CEO
- Tae-Jin Sim
- Full Time Employees
- 147
- Sector
- Health technology
- Industry
- Pharmaceuticals: other
- Address
- Yongin-si South Korea
- IPO Date
- Sep 28, 2021
- Website
- frombio.co.kr
- Similar Companies
- Business
- From Bio Co., Ltd. is a South Korea-based biotechnology and health functional food company that researches, develops, manufactures, and distributes dietary supplements, functional cosmeceuticals, and regenerative biopharmaceuticals. Founded in 2006 and headquartered in Yongin-si, Gyeonggi-do, South Korea, the company operates across the entire functional food value chain, encompassing ingredient discovery, clinical validation, regulatory approval, certified manufacturing, and omni-channel distribution. The company organizes its commercial operations into functional dietary supplements, specialized skincare, and animal health. Its core product portfolio comprises joint and cartilage health supplements formulated with individually recognized Boswellia serrata extracts, marketed under the Joint Cartilage Boswellia, Boswellia One Day, and Boswellia Easy product lines; gastrointestinal and gastric health solutions based on individually recognized Greek mastic gum, including Stomach Health Mastic, Stomach Health Mastic Double Action, and Mastic Probiotics; weight management and metabolic health supplements utilizing African wild mango seed extracts; men's vitality formulations containing saw palmetto and octacosanol; ocular health products featuring lutein and zeaxanthin complexes; comprehensive probiotic supplements, including the Family 365 Biome and The Kind Probiotics series; functional anti-aging, blemish-care, and brightening skincare cosmetics commercialized under the Mastina brand, anchored by White Mastic Core Ampoules; and companion animal dietary supplements and nutritional treats. From Bio operates Good Manufacturing Practice (GMP) and HACCP-certified production facilities in Iksan, Jeollabuk-do, along with specialized research institutes focused on natural bioactive substances and cell therapy. Its biopharmaceutical research pipeline develops cell-based therapeutics and hair growth promoters leveraging adipose-derived stem cells, hair follicle dermal papilla cells, and exosome technologies designed as non-hormonal treatments for alopecia. The company serves consumer markets domestically through TV home shopping networks, major health and beauty retail chains such as Olive Young, duty-free outlets, and proprietary direct-to-consumer online platforms, while maintaining an expanding international distribution footprint across Asia-Pacific markets, including mainland China, Hong Kong, Vietnam, and Japan. In recent corporate and strategic developments, From Bio completed a strategic equity investment in PepsGen to become its third-largest shareholder, reinforcing collaborative drug discovery and biotechnology capabilities. The company expanded its consumer healthcare offerings through the launch of the Family 365 Biome multi-functional probiotic line to diversify its revenue base beyond its flagship Boswellia and mastic franchises. Internationally, the company expanded retail distribution of its Mastina cosmeceutical brand into Japanese television home shopping and broadened its cross-border e-commerce networks across Hong Kong, Vietnam, and China via digital channels on Sa Sa, Shopee, Tmall, Douyin, and Kuaishou. To optimize its capital structure and enhance shareholder value, the company completed a 5-to-1 share consolidation and initiated an asset securitization program covering non-core operational real estate and logistics assets to enhance balance sheet liquidity and fund clinical advancement of its stem cell-derived hair loss pipeline.